Alexion Completes Acquisition of Enobia Pharma Corp.
CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the
Company has completed its previously announced acquisition of 100% of
the capital stock of Enobia Pharma Corp., a private biopharmaceutical
company focused on the development of therapies to treat patients with
ultra-rare and life-threatening genetic metabolic disorders.
Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and
Gray LLP acted as lead legal counsel to Alexion and Cassels Brock &
Blackwell LLP acted as Canadian legal counsel to Alexion.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on
serving patients with severe and ultra-rare disorders through the
innovation, development and commercialization of life-transforming
therapeutic products. Alexion is the global leader in complement
inhibition, and has developed and markets Soliris®
(eculizumab) as a treatment for patients with PNH and aHUS, two
debilitating, ultra-rare and life-threatening disorders caused by
chronic uncontrolled complement activation. Soliris is currently
approved in more than 35 countries for the treatment of PNH, and in the
United States and the European Union for the treatment of aHUS. Alexion
is evaluating other potential indications for Soliris and is developing
four other highly innovative biotechnology product candidates. This
press release and further information about Alexion Pharmaceuticals,
Inc. can be found at: www.alexionpharma.com.
Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Director, Corporate Communications
Mark Marmur, 212-508-9670
Rhonda Chiger, 917-322-2569
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media